Profusa 
What happened
PFSA completed its reverse stock split on Aug 17, 2026, reducing shares outstanding from approximately 2.4 million to about 556,791. The company announced the split via GlobeNewsWire on Aug 13. The initial reaction on Aug 17 sent the stock up roughly 27% to $4.53, and premarket trading on Aug 18 accelerated that move sharply higher.
At intraday highs on Aug 18, PFSA traded at $8.87, representing a roughly 211% gain from the prior session. Volume spiked to over 4.7 million shares, well above the average daily volume of roughly 925,000 shares based on short interest data as of late July. The float of approximately 87,591 shares (as of July 4 data) created extreme price sensitivity to any buying pressure, a hallmark of low-float microcap squeezes.
The split was the second reverse split for PFSA in 2026, following a 1-for-25 reverse split executed on July 2. The company completed a transfer to the Nasdaq Capital Market in May 2026, a move tied to maintaining listing compliance. In July, Profusa also announced management changes and signed a non-binding term sheet to acquire G3 Vision Labs, a commercial-stage diagnostics company. Shareholders previously approved a separate acquisition of the PanOmics platform to expand into precision diagnostics.
Why it matters
The PFSA move illustrates how dramatically a reverse split can reweight a microcap's float. With fewer shares outstanding, any retail buying wave translates into outsized percentage moves. Short interest of roughly 59,866 shares and days-to-cover near 1.0 suggest limited short pressure, yet the Aug 18 surge was driven entirely by speculative intraday flow rather than new fundamental catalysts.
From a research standpoint, PFSA's earnings on Aug 21 will be the next substantive data point. Prior results showed an EPS of negative $2.05 in May 2026 with no disclosed revenue, consistent with a pre-commercial-stage healthcare company. The G3 Vision Labs and PanOmics acquisitions remain at early stages and carry no confirmed close dates or revenue projections in disclosed materials.
What to watch next
First, PFSA earnings on Aug 21 will be closely watched for any update on the G3 Vision Labs acquisition timeline, PanOmics platform integration, or revenue visibility. Second, any regulatory or shareholder filings related to the proposed acquisitions will be key catalysts. Third, the stock's ability to hold above $5 will determine whether it avoids further compliance pressure on the Nasdaq Capital Market. Finally, any new press release or filing on Aug 18 clarifying the volume surge would shift the narrative from speculative momentum to potential corporate development.